Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
bCEHS6V6SJscLds9
